Anemia is a common complication in CKD (aCKD) and is associated with a reduced quality of life and increased morbidity and mortality. The mechanisms involved in aCKD are diverse and complex. They include a decrease in endogenous erythropoietin production, absolute and/or functional iron deficiency, and inflammation with increased hepcidin levels, among others. Patients are most commonly managed with oral or intravenous iron supplements and with erythropoiesis stimulating agents (ESA). However, these treatments have associated risks, and sometimes are insufficiently effective. Recently, there have been remarkable advances in the treatment of aCKD with hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). These agents induce an increase in the production of endogenous EPO, improve iron availability, and reduce hepcidin levels. Our expert faculty will review the current knowledge of the pathophysiology of aCKD, current and emerging therapies, trends in patient management, and unmet treatment goals.
Nephrologists, Hematologists, Primary Care, Internal Medicine, Hospitalists, Cardiologists, Endocrinologists, Family Medicine, APPs, and other healthcare providers who care for patients with chronic kidney disease.
I. Welcome and Introductions – Jay B. Wish, MD
II. Clinical Update for Anemia of CKD: Pathophysiology, Screening, Early Diagnosis, and Early Treatment of Anemia of CKD – Hector M. Madariaga, MD
III. Clinical Trial Analysis: Current and Emerging Therapies for Anemia of CKD and When to Apply – Daniel W. Coyne, MD and Jay B. Wish, MD
IV. Essential Clinical Strategies to Improve All Patients Outcomes: Modifying Treatments and Recognizing the Impact of Racial, Gender, and Socioeconomic Disparities in Patients with Anemia of CKD – Ellie Kelepouris, MD
V. Faculty Panel Discussion – Jay B. Wish, MD and Faculty
- Review the pathophysiology of anemia of CKD and the importance of screening, early diagnosis, and early treatment
- Analyze current clinical trial data and treatment options for managing patients with anemia of CKD
- Discuss the burden of disease and current racial, gender, and socioeconomic disparities in patients with anemia of CKD
Jay B. Wish, MD (Course Chair)
Medical Director, Out-Patient Dialysis Unit
Indiana University Hospital
Chief Medical Officer for Dialysis, IU Health
Professor of Clinical Medicine
Indiana University School of Medicine
Daniel W. Coyne, MD
Professor of Medicine
Director, Chromalloy American Kidney Center
Division of Nephrology
Washington University School of Medicine
St. Louis, Missouri
Ellie Kelepouris, MD
Professor of Clinical Medicine
Perelman School of Medicine
University of Pennsylvania
Hector M. Madariaga, MD
Lahey Hospital & Medical Center
Clinical Assistant Professor of Medicine
Tufts University School of Medicine
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Jay B. Wish, MD (Course Chair)||Consultant/Advisor: Akebia; AstraZeneca; CSL Behring; Dexcel Pharma; Disc Medicine; FibroGen, Inc.; GlaxoSmithKline; Otsuka Pharmaceutical; Rockwell Medical
Speaker’s Bureau: Akebia; AstraZeneca
|Daniel W. Coyne, MD||Consultant/Advisor: Akebia; AstraZeneca; Boehringer Ingelheim International GmbH; Daiichi Sankyo Company, Limited; FMC-Renal Therapies Group; Fresenius Kabi; Lilly; Otsuka Pharmaceutical; Travere Therapeutics, Inc.; Unicycive Therapeutics
Grant/Research Support: AstraZeneca
Speaker’s Bureau: AstraZeneca Canada; Fresenius Kabi
|Ellie Kelepouris, MD||Consultant/Advisor: Akebia; AstraZeneca; Bayer Pharmaceuticals; Boehringer Ingelheim International GmbH; GlaxoSmithKline; Relypsa; Up to Date
Speaker’s Bureau: AstraZeneca
|Hector M. Madariaga, MD||Consultant/Advisor: Vifor Medical|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM.
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from GlaxoSmithKline.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and GlaxoSmithKline do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].